Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7506.091 | 0.0087 | -0.9722 | 1.1096 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7507.09 | 1.0140 | 1.0276 | 1.0118 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7507.09 | 1.0081 | 1.0159 | 1.0118 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7507.09 | 1.0137 | 1.0270 | 1.0118 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7507.09 | 1.0270 | 1.0534 | 1.0118 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7507.09 | 1.0258 | 1.0509 | 1.0118 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7507.09 | 0.9978 | 0.9957 | 1.0118 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7507.09 | 0.8464 | 0.6962 | 1.0118 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7507.09 | 0.0156 | -0.9672 | 1.0118 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7507.09 | 0.0087 | -0.9817 | 1.0118 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7508.091 | 0.9498 | 0.8511 | 0.6662 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7508.091 | 1.0072 | 1.0218 | 0.6662 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7508.091 | 0.9699 | 0.9104 | 0.6662 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7508.091 | 0.9804 | 0.9415 | 0.6662 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7508.091 | 0.9839 | 0.9520 | 0.6662 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7508.091 | 0.9749 | 0.9252 | 0.6662 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7508.091 | 0.8411 | 0.5426 | 0.6662 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7508.091 | 0.0145 | -0.9965 | 0.6662 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7508.091 | 0.0063 | -0.9990 | 0.6662 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7510.09 | 0.9817 | 0.9666 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7510.09 | 1.0197 | 1.0358 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7510.09 | 0.9023 | 0.8210 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7510.09 | 0.8568 | 0.7369 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7510.09 | 0.9321 | 0.8756 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7510.09 | 1.0215 | 1.0392 | 1.0960 |